We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Singapore Chinese Health Study (SCHS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03356340
Recruitment Status : Active, not recruiting
First Posted : November 29, 2017
Last Update Posted : November 29, 2017
Information provided by (Responsible Party):

November 23, 2017
November 29, 2017
November 29, 2017
April 1, 1993
December 31, 2025   (Final data collection date for primary outcome measure)
  • Cancer incidence [ Time Frame: 1993 to 2025 ]
    Linkage to national cancer registry
  • End-stage Renal Disease [ Time Frame: 1993 to 2025 ]
    Linkage to national renal registry
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
The Singapore Chinese Health Study
The Singapore Chinese Health Study
The "Singapore Chinese Health Study" is a cohort study established by the Department of Epidemiology and Public Health in National University of Singapore, together with collaborators from several universities in the United States of America. This is a long-term study to help doctors and scientists understand the influence of diet, lifestyle and environment on the development of common diseases among Singaporean men and women. This includes cancer, heart disease, stroke, dementia, osteoporosis, high cholesterol and diabetes. The aim is to help us understand the causes of these diseases and to discover effective and efficient approaches for prevention and treatment.
The cohort consists of more than 60,000 men and women who were enrolled in the Singapore Chinese Health Study during 1993-1998. At the time of enrollment, participants were interviewed in-person regarding their dietary habits and other lifestyle factors. About half of them also donated small amounts of blood and urine for research between 2000 and 2004.
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Beginning in April 1994, a 3% random sample of enrollees were re-contacted for donation of blood/buccal cells and spot urine specimens. In January 2001, the accrual of biospecimens was extended to include all consenting cohort enrollees. Hitherto, biospecimens have been collected from about 32,800 subjects (28,439 bloods, 4,438 buccal cells, 31,201 urines), representing a consent rate of about 60%.
Non-Probability Sample
The study was established between April 1993 and December 1998 through the recruitment of a residential cohort of 63,257 Chinese men (n=27,959) and women (n=35,298), who were aged 45-74 years, and residing in public housing estates.
  • Cancer
  • End Stage Renal Disease
  • Diabetes
  • Cardiovascular Diseases
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Active, not recruiting
December 31, 2025
December 31, 2025   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Housing estate residents, ages 45-74 years, Chinese

Exclusion Criteria:

Sexes Eligible for Study: All
45 Years to 74 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Woon-Puay Koh, Duke-NUS Graduate Medical School
Duke-NUS Graduate Medical School
Not Provided
Not Provided
Duke-NUS Graduate Medical School
November 2017